AlprostadilvsMelanotan II

Alprostadil is synthetic prostaglandin E1 (PGE1), a 20-carbon oxygenated fatty acid derived from dihomo-gamma-linolenic acid (DGLA) through the cyclooxygenase pathway. It acts locally on penile vascular and trabecular smooth muscle through two prostaglandin E receptor subtypes: EP2 and EP4, both of which are Gs-coupled GPCRs that increase intracellular cAMP upon activation.

Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple targets in smooth muscle cells to produce relaxation. PKA phosphorylates myosin light chain kinase (MLCK), reducing its affinity for the calcium-calmodulin complex and decreasing its ability to phosphorylate myosin light chains — the final step in smooth muscle contraction. PKA also activates calcium-ATPase pumps and opens potassium channels, reducing intracellular calcium concentration. The net effect is relaxation of both the helicine arterioles (which supply blood to the corpora cavernosa) and the trabecular smooth muscle (which forms the spongy erectile tissue). As these relax, blood flows into the sinusoidal spaces of the corpora cavernosa, expanding the tissue against the tunica albuginea and compressing the subtunical veins — trapping blood and producing an erection.

The critical distinction of alprostadil's mechanism is its direct, local action independent of central sexual arousal pathways and independent of nitric oxide. PDE5 inhibitors (sildenafil, etc.) work by preventing cGMP breakdown downstream of nitric oxide release, which requires sexual arousal to generate the initial NO signal. Alprostadil generates its own second messenger (cAMP) at the injection site regardless of arousal state, which is why it produces erections reliably even in patients with neurogenic erectile dysfunction (spinal cord injury, radical prostatectomy) where the nerve-mediated NO pathway is damaged. The extremely rapid pulmonary metabolism (80% cleared in a single pass through the lungs) ensures that systemic effects are minimal when administered locally.

Melanotan II is a synthetic cyclic heptapeptide analogue of α-MSH with a fundamentally different receptor profile from the linear Melanotan I. Its cyclic structure (achieved through a lactam bridge between aspartic acid and lysine residues) provides metabolic stability and, critically, non-selective binding to multiple melanocortin receptors (MC1R through MC5R), producing a diverse range of physiological effects.

MC1R activation on melanocytes drives the same eumelanin production pathway as MT-I: cAMP → PKA → CREB → MITF → tyrosinase/TRP-1/TRP-2, resulting in skin darkening independent of UV exposure. However, MT-II's additional activation of MC3R and MC4R in the hypothalamus produces effects that MT-I does not. MC4R is a key regulator of sexual function and energy balance — its activation in the paraventricular nucleus stimulates sexual arousal and erectile function through descending autonomic pathways, while simultaneously suppressing appetite through inhibition of orexigenic NPY/AgRP neurons. This is why MT-II produces the notable combination of tanning, increased libido, and reduced appetite.

MC3R activation contributes to energy homeostasis regulation and may modulate natriuresis (sodium excretion). MC5R activation on exocrine glands may affect sebaceous gland secretion. The non-selective nature of MT-II's receptor activation is both its appeal (multiple desired effects from one compound) and its primary safety concern — the broad melanocortin activation means effects cannot be isolated, and the tanning effect raises concerns about melanocyte stimulation in pre-existing moles and nevi. Unlike MT-I, which received FDA approval for a specific indication, MT-II's non-selective profile and cosmetic use case have prevented regulatory approval, and it is actively discouraged by health authorities in most countries.